Expression, purification, and characterization of the native intracellular domain of human epidermal growth factor receptors 1 and 2 in Escherichia coli
Human epidermal growth factor receptors (EGFR) are an important target in drug discovery in terms of both protein–small-molecule interactions and protein–protein interactions. In this work, the isolation of a stable soluble protein of the tyrosine kinase domain of EGFR in Escherichia coli expression has been accomplished. This successful study presents the expression and purification conditions to obtain a stable soluble protein of the active tyrosine kinase domain of EGFR (EGFR-TK) and ErbB2 (ErbB2-TK) in a bacterial system, albeit in relatively low yields. The recombinant gene was inserted into a pColdI vector and recombinant protein was expressed at low temperature. Purification of EGFR-TK and ErbB2-TK took place under the same conditions by purified supernatant using a diethylaminoethyl sepharose column followed by anion exchange and size-exclusion chromatography columns. The final yields of purified EGFR-TK and ErbB2-TK were 8.4 and 9.5 mg per liter of culture, respectively. Determination of EGFR-TK and ErbB2-TK was performed via enzyme activity with commercial drugs. The IC50 values of erlotinib and afatinib against EGFR-TK were 13.09 nM and 2.36 nM respectively, while the IC50 values of lapatinib and afatinib against ErbB2-TK were 24.69 nM and 1.36 nM, respectively. These results confirmed that soluble proteins of the active intracellular domain of the HERs family were successfully expressed and purified in a bacterial system. The new protein expression and purification protocol will greatly facilitate the enzymatic inhibition and structural studies of this protein for drug discovery.
KeywordsEpidermal growth factor receptor EGFR ErbB2 Tyrosine kinase Active enzyme Bacterial expression
The authors would like to sincerely thank the National Omics Center, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Thailand for LC-MS/MS Technology.
This work was supported by the Thailand Research Fund (RSA6080078 and DBG6080007) and the Center for Advanced Studies in Nanotechnology for Chemical, Food and Agricultural Industries, KU Institute for Advanced Studies, Kasetsart University and Development Institute. This research was also supported by Joint Research and by Exploratory Research Center on Life and Living Systems (ExCELLS), Japan (ExCELLS program No. 18-101 to H.W. and No. 19-310 to K.C.).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- Baselga J, Cortes J (2005) Epidermal growth factor receptor pathway inhibitors. Cancer Chemother Biol Response Modif 22:205–23. https://doi.org/10.1016/j.uct.2006.08.002
- Cha MY, Lee KO, Kang SJ, Jung YH, Song JY, Choi KJ, Byun JY, Lee HJ, Lee GS, Park SB, Kim MS (2012) Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases. J Med Chem 55(6):2846–2857. https://doi.org/10.1021/jm201758g CrossRefGoogle Scholar
- Ciardiello F, Caputo R, Troiani T, Borriello G, Kandimalla ER, Agrawal S, Mendelsohn J, Bianco AR, Tortora G (2001) Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer 93(2):172–178. https://doi.org/10.1002/ijc.1335 CrossRefGoogle Scholar
- Coumar MS, Chu CY, Lin CW, Shiao HY, Ho YL, Reddy R, Lin WH, Chen CH, Peng YH, Leou JS, Lien TW, Huang CT, Fang MY, Wu SH, Wu JS, Chittimalla SK, Song JS, Hsu JT, Wu SY, Liao CC, Chao YS, Hsieh HP (2010) Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification. J Med Chem 53(13):4980–4988. https://doi.org/10.1021/jm1000198 CrossRefGoogle Scholar
- Di Massimo AM, Di Loreto M, Pacilli A, Raucci G, D’Alatri L, Mele A, Bolognesi A, Polito L, Stirpe F, De Santis R (1997) Immunoconjugates made of an anti-EGF receptor monoclonal antibody and type 1 ribosome-inactivating proteins from Saponaria ocymoides or Vaccaria pyramidata. Br J Cancer 75(6):822–828. https://doi.org/10.1038/bjc.1997.147 CrossRefGoogle Scholar
- Dong A, Wodziak D, Lowe AW (2015) Epidermal growth factor receptor (EGFR) signaling requires a specific endoplasmic reticulum thioredoxin for the post-translational control of receptor presentation to the cell surface. J Biol Chem 290(13):8016–8027. https://doi.org/10.1074/jbc.M114.623207 CrossRefGoogle Scholar
- Ferguson KM (2008) Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys 37:353–373. https://doi.org/10.1146/annurev.biophys.37.032807.125829 CrossRefGoogle Scholar
- Galizia G, Lieto E, De Vita F, Orditura M, Castellano P, Troiani T, Imperatore V, Ciardiello F (2007) Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 26(25):3654–3660. https://doi.org/10.1038/sj.onc.1210381 CrossRefGoogle Scholar
- Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM (2011) EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18(1):74–82. https://doi.org/10.1038/nm.2577 CrossRefGoogle Scholar
- Holbro T, Hynes NE (2004) ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 44:195–217 https://doi.org/10.1146/annurev.pharmtox.44.1018
- Knowles JA, Heath CH, Saini R, Umphrey H, Warram J, Hoyt K, Rosenthal EL (2012) Molecular targeting of ultrasonographic contrast agent for detection of head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 138(7):662–668. https://doi.org/10.1001/archoto.2012.1081 CrossRefGoogle Scholar
- Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139. https://doi.org/10.1056/NEJMoa040938 CrossRefGoogle Scholar
- Mahboobi S, Sellmer A, Winkler M, Eichhorn E, Pongratz H, Ciossek T, Baer T, Maier T, Beckers T (2010) Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity. J Med Chem 53(24):8546–8555. https://doi.org/10.1021/jm100665z CrossRefGoogle Scholar
- Niculescu-Duvaz I (2010) Trastuzumab emtansine, an antibody-drug conjugate for the treatment of HER2+ metastatic breast cancer. Curr Opin Mol Ther 12(3):350–360Google Scholar
- Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500. https://doi.org/10.1126/science.1099314 CrossRefGoogle Scholar
- Riese DJ 2nd, Stern DF (1998) Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20(1):41–48. https://doi.org/10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V CrossRefGoogle Scholar
- Sun Y, Feng X, Qu J, Han W, Liu Z, Li X, Zou M, Zhen Y, Zhu J (2015) Expression and characterization of the extracellular domain of human HER2 from Escherichia Coli, and production of polyclonal antibodies against the recombinant proteins. Appl Biochem Biotechnol 176(4):1029–1043. https://doi.org/10.1007/s12010-015-1627-x CrossRefGoogle Scholar
- Suzuki N, Shiota T, Watanabe F, Haga N, Murashi T, Ohara T, Matsuo K, Omori N, Yari H, Dohi K, Inoue M, Iguchi M, Sentou J, Wada T (2012) Discovery of novel 5-alkynyl-4-anilinopyrimidines as potent, orally active dual inhibitors of EGFR and Her-2 tyrosine kinases. Bioorg Med Chem Lett 22(1):456–460. https://doi.org/10.1016/j.bmcl.2011.10.103 CrossRefGoogle Scholar
- van der Geer P, Hunter T, Lindberg RA (1994) Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10:251–337. https://doi.org/10.1146/annurev.cb.10.110194.001343 CrossRefGoogle Scholar
- Wang GT, Mantei RA, Hubbard RD, Wilsbacher JL, Zhang Q, Tucker L, Hu X, Kovar P, Johnson EF, Osterling DJ, Bouska J, Wang J, Davidsen SK, Bell RL, Sheppard GS (2010) Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases. Bioorg Med Chem Lett 20(20):6067–6071. https://doi.org/10.1016/j.bmcl.2010.08.052 CrossRefGoogle Scholar
- Ward RA, Anderton MJ, Ashton S, Bethel PA, Box M, Butterworth S, Colclough N, Chorley CG, Chuaqui C, Cross DA, Dakin LA, Debreczeni JE, Eberlein C, Finlay MR, Hill GB, Grist M, Klinowska TC, Lane C, Martin S, Orme JP, Smith P, Wang F, Waring MJ (2013) Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). J Med Chem 56(17):7025–7048. https://doi.org/10.1021/jm400822z CrossRefGoogle Scholar
- Zhang F, Wang S, Yin L, Yang Y, Guan Y, Wang W, Xu H, Tao N (2015a) Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging. Anal Chem 87(19):9960–9965. https://doi.org/10.1021/acs.analchem.5b02572 CrossRefGoogle Scholar
- Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4(2):67–73. https://doi.org/10.1177/108705719900400206